"He went through six operations and was placed on a clinical trial so he could try new treatments.”
A trial of radiotherapy with or without chemotherapy after surgery for oligodendroglioma brain tumours (EORTC 26951)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
Doctors often treat oligodendroglioma brain tumours with surgery and radiotherapy. Many people also have a combination of chemotherapy called PCV to try to stop their cancer coming back. PCV is procarbazine, lomustine, and vincristine.
The aims of this trial were to find out
- If having radiotherapy and chemotherapy after surgery is better than having radiotherapy alone
- More about the side effects
Summary of results
The trial team found that PCV was not a useful treatment for people with oligodendroglioma brain tumours after surgery and radiotherapy.
368 people took part in this trial. After surgery
- Half had radiotherapy
- Half had radiotherapy and chemotherapy (PCV)
The researchers analysed the results in 2008. They compared the 2 groups. In the PCV group it took longer before there were any signs of the cancer getting worse. But overall they found no difference in how many people lived for 5 years after treatment.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Martin J. Van den Bent
European Organisation for Research and Treatment of Cancer (EORTC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer